eligibility_summary
Eligible: 18–60, severe asthma (GINA 2022), starting a biologic, otherwise healthy, can do lung function tests/use devices and comply, gives consent. Exclude: recent/unresolved COVID-19, high-dose oral steroids in last 6 wks, another biologic in last 3 mos, cannot perform spirometry/IOS/FeNO or use Respicorder, current smoker/vaper, drug use, >10 pack-years, noncompliance or medically unsafe, cannot read Dutch.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Observational cohort of severe asthma patients initiating standard-of-care biologic immunotherapy. Interventions (all monoclonal antibodies): mepolizumab (anti–IL-5, blocks IL-5 to reduce eosinophil survival), reslizumab (anti–IL-5, similar), benralizumab (anti–IL-5Rα, induces ADCC to deplete eosinophils/basophils), omalizumab (anti-IgE, neutralizes free IgE and downregulates FcεRI on mast cells/basophils), dupilumab (anti–IL-4Rα, blocks IL-4/IL-13 signaling, dampening type 2 inflammation). Cells/pathways targeted: eosinophils, basophils, mast cells, IL-5/IL-5R axis, IgE–FcεRI allergic pathway, IL-4/IL-13 (Th2/type 2) via STAT6. Biomarker fluctuations (spirometry, FeNO, IOS) are tracked to predict early treatment response.